Combine EUROPA and HOPE [2]

Lancet

Volumn 362, Issue 9399, 2003, Pages 1937-

  Fuller, John A ^a  

^a EPWORTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PERINDOPRIL; RAMIPRIL;

CARDIOVASCULAR SYMPTOM; CLINICAL RESEARCH; CLINICAL TRIAL; DATA ANALYSIS; DRUG INDUSTRY; HEART PROTECTION; HUMAN; INTERMETHOD COMPARISON; LETTER; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION;

EID: 0345549407     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14976-8     Document Type: Letter

References (2)

1. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-88.
2. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.